Acadia Pharmaceuticals Inc

NASDAQ:ACAD   3:59:52 PM EDT
16.74
+0.46 (+2.83%)
Products

Acadia Pharmaceuticals Announces Trofinetide New Drug Application For The Treatment Of Rett Syndrome Has Been Accepted For Filing And Review By U.S. FDA

Published: 09/12/2022 11:46 GMT
Acadia Pharmaceuticals Inc (ACAD) - Acadia Pharmaceuticals Announces Trofinetide New Drug Application for the Treatment of Rett Syndrome Has Been Accepted for Filing and Review by U.S. FDA.
Acadia Pharmaceuticals Inc - NDA Granted Priority Review.
Acadia Pharmaceuticals Inc - Prescription Drug User Fee Act Action Date Set for March 12, 2023.
Acadia Pharmaceuticals Inc - FDA Informed Company That at This Time They Are Not Planning to Hold an Advisory Committee Meeting.